Who is sponsoring NCT00564395?

NCT00564395 is sponsored by Montefiore Medical Center.

What condition does NCT00564395 study?

NCT00564395 studies Type 1 Diabetes Mellitus.

What drugs are being tested in NCT00564395?

Interventions: Insulin Detemir mixed with RAI injection, Insulin Detemir and RAI injection.

What is the status of NCT00564395?

NCT00564395 is currently COMPLETED.

Last reviewed 2018-07-13 · How we verify

Role of Insulin Aspart and Detemir to Assess Glucose Excursion in Children With Type 1 Diabetes

NCT00564395 Phase 4 COMPLETED Results posted

Study of blood sugars in the children with Type 1 Diabetes Mellitus (T1DM), who are given insulin detemir and a rapid acting insulin (aspart). It is hypothesized that there is no difference in the patterns of blood sugars when detemir is given in the same syringe or in separate syringes with rapid acting insulin.

Details

Lead sponsor	Montefiore Medical Center
Phase	Phase 4
Status	COMPLETED
Enrolment	18
Start date	2007-08
Completion	2010-05

Conditions

Type 1 Diabetes Mellitus

Interventions

Insulin Detemir mixed with RAI injection
Insulin Detemir and RAI injection

Primary outcomes

Assess the Mean Area Under the Curve (AUC) for Blood Glucose Concentration in Subjects Treated With Either Insulin Detemir Mixed With Rapid Acting Insulin (RAI) or Insulin Detemir and RAI as Separate Subcutaneous Injections — 0-48 hours post-dose
Blood glucose concentration in terms of mean AUC (0-48 hours)was determined in subjects treated with either Insulin Detemir mixed with RAI or Insulin Detemir and RAI as separate subcutaneous injections.

Countries

United States